PF-05089771

N/A

Report date: 2023/07/10 20:00:27
NME

Base Information

Drug NamePF-05089771
Drug Alias NamePF-5089771PF-05089771
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type IX alpha subunit blockers
TargetsSodium channel protein type IX alpha subunit
Therapy Area/IndicationsPainPain, PostoperativeErythromelalgia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesMedical University Of Vienna
Inactive CompaniesPfizer Inc
Active IndicationsPain
Inactive IndicationsPain, PostoperativeErythromelalgiaDiabetic Neuropathies

Other Information

ATC CodeN/A
Related LinksWikipedia